Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Chronic pulmonary aspergillosis (CPA) is a serious long-term fungal disease of the lung with a worldwide prevalence. Chronic pulmonary aspergillosis (CPA) complicates conditions including tuberculosis, chronic obstructive pulmonary disease and sarcoidosis, and is associated with high morbidity and mortality. Chronic pulmonary aspergillosis (CPA) is characterized by slowly progressive destruction of lung parenchyma, in the form of single of multiple cavities, nodules, infiltrates or fibrosis, with or without an aspergilloma.

The global chronic aspergillosis treatment market is estimated to be valued at US$ 2,916.3 million in 2021 and is expected to exhibit a CAGR of 4.8 % during the forecast period (2021-2028).

Figure 1.Global Chronic Aspergillosis Treatment Market Share (%) in Terms of Value, By Drug Class, 2021

Chronic Aspergillosis Treatment  | Coherent Market Insights

Increasing incidence and prevalence of aspergillosis is expected to drive the market growth during the forecast period.

Increasing prevalence of aspergillosis is expected to drive the global chronic aspergillosis treatment market growth over the forecast period. For instance, according to the National Organization for Rare Disorders, aspergillosis has been reported from all over the world in recent years. Allergic bronchopulmonary aspergillosis has been estimated to affect about one to four million people worldwide annually. Moreover, according to the same source, chronic pulmonary aspergillosis is estimated to affect about three million people worldwide every year.

request-sample

Chronic Aspergillosis Treatment Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 2,916.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 4.8% 2028 Value Projection: US$ 4,056.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Corticosteroids, Anti-fungal Drugs
  • By Disease Type: Simple Aspergilloma, Chronic Cavitary Pulmonary Aspergillosis, Chronic Fibrosing Pulmonary Aspergillosis, Subacute Invasive Aspergillosis, Allergic Bronchopulmonary Aspergillosis [ABPA], Severe Asthma With Fungal Sensitization [SAFS]
  • By Distribution Channel: Hospital Pharmaciesm, Retail Pharmacies and Drug Store, E-commerce
Companies covered:

Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG

Growth Drivers:
  • Increasing incidence and prevalence of aspergillosis
  • Robust product pipeline
Restraints & Challenges:
  • Increasing generic competition
  • Complications associated with drugs used in the treatment of chronic aspergillosis

Figure 2.Global Chronic Aspergillosis Treatment Market Share (%), By Disease Type, 2021

Chronic Aspergillosis Treatment  | Coherent Market Insights

Robust product pipeline of chronic aspergillosis is expected to drive the market growth during the forecast period.

Robust product pipeline for the treatment of chronic aspergillosis which are expected to launch during the forecast period is anticipated to drive the growth of the global chronic aspergillosis treatment market. For instance, on September 15, 2020, Regeneron Pharmaceuticals, a biopharmaceutical company, initiated phase III, a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dupilumab in patients with allergic bronchopulmonary aspergillosis. The study is estimated to be completed by October 23, 2023.

Global Chronic Aspergillosis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

According to Centers for Disease Control and Prevention, investigators in Spain and the U.S. added 20 new case reports to mounting evidence that patients with coronavirus disease 2019 (COVID-19) are at risk of developing pulmonary aspergillosis. The coronavirus (COVID 19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the medication used in treatment of chronic aspergillosis such as antifungal drugs and corticosteroids manufactured by various companies across the regions such as North America, Europe, and Asia Pacific. The supply and production of pharmaceutical products is also affected due to COVID-19 pandemic lockdown imposed globally. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of the pharmaceutical products. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) By directly affecting the production and demand; 2) By creating disruptions in distribution channels; and 3) By its financial impact on firms and financial markets. Thus, the impact of coronavirus (COVID-19) pandemic is expected to limit growth of the global chronic aspergillosis treatment market during the forecast period

Global Chronic Aspergillosis Treatment Market: Restraint

The major factors that are expected to hinder growth of the global chronic aspergillosis treatment market include increasing generic competition and complications associated with drugs used in the treatment of chronic aspergillosis. For instance, in November 2016, Ajanta Pharma, a pharmaceutical company, launched voriconazole tablets in 50-mg and 200-mg doses in the U.S. market. These tablets are the equivalent generic version of Vfend, an antifungal drug from Pfizer. Vfend is used to treat conditions such as invasive aspergillosis, candidemia, and serious infections caused by Scedosporium apiospermum and Fusarium species.

Key Players

Major players operating in the global chronic aspergillosis treatment market include Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG

Aspergillosis is a group of diseases that occur from aspergillus infection. Aspergillus is a fungus whose spores are present in the air, but does not normally cause illness. Individuals with damaged lungs, sensitive immune system, and allergies are more prone to aspergillus induced infection. Common aspergillus infections include invasive aspergillosis, non-invasive Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary Aspergilloma (CPA). Azoles are the only oral drug with anti-aspergillus activity and itraconazole and voriconazole are considered as first-line drugs for chronic pulmonary aspergillosis.

Market Dynamics

Key players operating in the market are focusing on development and approval of novel therapeutics for the treatment of chronic aspergillosis, which is expected to offer a lucrative opportunity to the market players to launch innovative products in the market for the treatment of aspergillosis. For instance, In October 2017, Mylan N.V. launched caspofungin acetate for injection, one of the first generic versions of the U.S. pharma giant Merck's & Co’s Cancidas. It is indicated for invasive aspergillosis in patients who are refractory to or intolerant of other therapies. Furthermore, key companies in the market focusing on growth strategies such as FDA approvals which is expected to drive the growth of the market over forecast period. For instance, In January 2020, PULMATRiX, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to PUR1900 (Pulmazole). The company's inhaled itraconazole antifungal candidate is developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Key features of the study:

  • This report provides in-depth analysis of the global chronic aspergillosis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chronic aspergillosis treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global chronic aspergillosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic aspergillosis treatment market

Detailed Segmentation:

  • Global Chronic Aspergillosis Treatment Market, By Drug Class :
    • Corticosteroids
    • Anti-fungal Drugs
  • Global Chronic Aspergillosis Treatment Market, By Disease Type :
    • Simple Aspergilloma
    • Chronic Cavitary Pulmonary Aspergillosis
    • Chronic Fibrosing Pulmonary Aspergillosis
    • Subacute Invasive Aspergillosis
    • Allergic Bronchopulmonary Aspergillosis [ABPA]
    • Severe Asthma With Fungal Sensitization [SAFS]
  • Global Chronic Aspergillosis Treatment Market, By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies and Drug Store
    • E-commerce
  • Global Chronic Aspergillosis Treatment Market, By Region:
    • North America
      • By Drug Class
        • Corticosteroids
        • Anti-fungal Drugs
      • By Disease Type
        • Simple Aspergilloma
        • Chronic Cavitary Pulmonary Aspergillosis
        • Chronic Fibrosing Pulmonary Aspergillosis
        • Subacute Invasive Aspergillosis
        • Allergic Bronchopulmonary Aspergillosis [ABPA]
        • Severe Asthma With Fungal Sensitization [SAFS]
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies and Drug Store
        • E-commerce
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Class
        • Corticosteroids
        • Anti-fungal Drugs
      • By Disease Type
        • Simple Aspergilloma
        • Chronic Cavitary Pulmonary Aspergillosis
        • Chronic Fibrosing Pulmonary Aspergillosis
        • Subacute Invasive Aspergillosis
        • Allergic Bronchopulmonary Aspergillosis [ABPA]
        • Severe Asthma With Fungal Sensitization [SAFS]
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies and Drug Store
        • E-commerce
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class
        • Corticosteroids
        • Anti-fungal Drugs
      • By Disease Type
        • Simple Aspergilloma
        • Chronic Cavitary Pulmonary Aspergillosis
        • Chronic Fibrosing Pulmonary Aspergillosis
        • Subacute Invasive Aspergillosis
        • Allergic Bronchopulmonary Aspergillosis [ABPA]
        • Severe Asthma With Fungal Sensitization [SAFS]
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies and Drug Store
        • E-commerce
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • Corticosteroids
        • Anti-fungal Drugs
      • By Disease Type
        • Simple Aspergilloma
        • Chronic Cavitary Pulmonary Aspergillosis
        • Chronic Fibrosing Pulmonary Aspergillosis
        • Subacute Invasive Aspergillosis
        • Allergic Bronchopulmonary Aspergillosis [ABPA]
        • Severe Asthma With Fungal Sensitization [SAFS]
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies and Drug Store
        • E-commerce
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class
        • Corticosteroids
        • Anti-fungal Drugs
      • By Disease Type
        • Simple Aspergilloma
        • Chronic Cavitary Pulmonary Aspergillosis
        • Chronic Fibrosing Pulmonary Aspergillosis
        • Subacute Invasive Aspergillosis
        • Allergic Bronchopulmonary Aspergillosis [ABPA]
        • Severe Asthma With Fungal Sensitization [SAFS]
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies and Drug Store
        • E-commerce
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • Corticosteroids
        • Anti-fungal Drugs
      • By Disease Type
        • Simple Aspergilloma
        • Chronic Cavitary Pulmonary Aspergillosis
        • Chronic Fibrosing Pulmonary Aspergillosis
        • Subacute Invasive Aspergillosis
        • Allergic Bronchopulmonary Aspergillosis [ABPA]
        • Severe Asthma With Fungal Sensitization [SAFS]
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies and Drug Store
        • E-commerce
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Astellas Pharma Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Abbott Laboratories
    • Pfizer Inc.
    • Pulmocide Ltd.
    • Johnson & Johnson
    • Mylan N.V.
    • Glenmark Pharmaceuticals
    • Merck & Co., Inc.
    • Mayne Pharma Group Limited
    • GlaxoSmithKline plc.
    • PULMATRiX, Inc.
    • F2G Ltd
    • Teva Pharmaceutical Industries Ltd.
    • Novartis International AG

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Disease Type
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Key Developments
    • Market Trends
    • Epidemiology
    • Incidence rate of Chronic Aspergillosis (Asthma, COPD, Bronchiectasis, and others)
    • Product Approvals/Launches
    • Pipeline Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Merger, Acquisition & Agreements
    • Treatment Algorithm
  4. Global Chronic Aspergillosis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
    • Supply and Demand Analysis
    • COVID-19 Impact on Clinical Trials
    • Economic Impact
  5. Global Chronic Aspergillosis Treatment Market, By Drug Class, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Anti-fungal Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global Chronic Aspergillosis Treatment Market, By Disease Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Simple Aspergilloma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Chronic Cavitary Pulmonary Aspergillosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Chronic Fibrosing Pulmonary Aspergillosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Subacute Invasive Aspergillosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Allergic Bronchopulmonary Aspergillosis [ABPA]
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Severe Asthma With Fungal Sensitization [SAFS]
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  7. Global Chronic Aspergillosis Treatment Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
        • Hospital Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
        • Retail Pharmacies and Drug Store
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
        • E-commerce
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  8. Global Chronic Aspergillosis Treatment Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2028
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Region/Countries, 2017 – 2028, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Astellas Pharma Inc.*
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Abbott Laboratories
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Pfizer Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Pulmocide Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Mylan N.V.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Glenmark Pharmaceuticals
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Merck & Co., Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Mayne Pharma Group Limited
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • PULMATRiX, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • F2G Ltd
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Novartis International AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
    • Analyst Views
  10. Section
    • Research Methodology
    • About us

*Browse 35 market data tables and 33 figures on "Chronic Aspergillosis Treatment Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global chronic aspergillosis treatment market size is estimated to be valued at US$ 2,916.3 Mn in 2021 and is expected to exhibit a CAGR of 4.8% between 2021 and 2028.
Factors such as increasing incidence and prevalence of aspergillosis and robust product pipeline are expected to drive the market growth during the forecast period.
Anti-fungal drugs segment is expected to hold a major market share during the forecast period.
The major factors hampering growth of the market include increasing generic competition and complications associated with drugs used in the treatment of chronic aspergillosis.
Major players operating in the market include Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.